The Early Career Investigator Committee (ECIC)

 Twitter @ANZBMS_ECIC

 

Definition of an Early Career Investigator

Current higher degree or current researcher within 10 years from the award of a higher degree (e.g. PhD/Masters).

 

Mission

The mission of the Early Career Investigator Committee (ECIC), formed in February 2017, is to help shape the future of bone and mineral research in Australia and New Zealand by fostering active engagement of early career investigators within the Australia & New Zealand Bone and Mineral Society (ANZBMS), supporting professional development of early career investigators and facilitating interactions between junior and senior members of all disciplines.

 

Objectives

 

Committee

Co-Chairs   

Ayse Zengin and Melissa Cantley

Career Development Representatives 

John Kemp, Sarah Hosking

Clinical Training Representatives

Alicia Jones

Communications Representatives 

Melissa Cantley, Victoria Leitch

Events Representatives                            

Ayse Zengin, Natalie Hyde

ECIC representative to ANZBMS POC

TBD

 

 

Dr Ayse Zengin

Roles: ECIC Co-Chair, Events

Research Fellow, Bone and Muscle Health Research, Monash University

Researcher Profile: https://research.monash.edu/en/persons/ayse-zengin

Twitter: @DrAyseZ

Email: ayse.zengin@monash.edu

Dr Ayse Zengin is a Research Fellow investigating global musculoskeletal health and diseases – in particular osteoporosis, fracture risk and sarcopenia. Her studies are based in the ageing populations of low-middle income countries (The Gambia, West Africa and India) and Indigenous Australians. Using the latest bone imaging modalities in combination with novel muscle functional assessment (e.g. jumping mechanography) and assessing the effects of lifestyle factors (diet, physical activity, vitamin D), her findings will shed light on the prevalence of these diseases and formulate preventative strategies for the global ageing population.

 

Dr Melissa Cantley

Roles: ECIC Co-Chair, Communications

NHMRC Early Career Research Fellow, Myeloma Research Laboratory, Adelaide Medical School, Faculty of Health and Medical Sciences, The University of Adelaide

Researcher Profile: https://researchers.adelaide.edu.au/profile/melissa.cantley

Email: melissa.cantley@adelaide.edu.au

Dr Melissa Cantley is a NHMRC Early Career Fellow working in the Myeloma Research Laboratory at the University of Adelaide, located at SAHMRI. Her research interest focuses on targeting bone cells, osteoclasts and osteoblasts to suppress pathogenic bone loss in chronic inflammatory diseases and understanding the role these cells and abnormal bone remodelling processes play in the progression of pre-cancerous stages to the haematological malignancy multiple myeloma.

  

Dr John Kemp

Role: Career Development

NHMRC Emerging Leadership Fellow

University of Queensland Diamantina Institute, Faculty of Medicine, University of Queensland.

Researcher Profile: http://researchers.uq.edu.au/researcher/8866

Email: j.kemp2@uq.edu.au

Dr John Kemp is a genetic epidemiologist, and National Health and Medical Research Council Emerging Leadership Fellow. His research aims to identify pharmacological targets for osteoporosis intervention by applying innovative statistical and molecular genetic methods to the world’s largest genetic study of osteoporosis.

 

Dr Alex Barker

Role: TBD

Research Associate, UniSA

Researcher Profile: https://people.unisa.edu.au/Alex.Barker

Twitter:@DrAlexBarker

Email: alex.barker@unisa.edu.au

Dr. Barker is currently leading and managing the preclinical phase on an industry/CRC funded project, alongside other researchers to develop antimicrobial orthopaedic devices. Prior to this project which began in 2018, Dr. Barker completed her PhD in Medicine at the University of Adelaide, where she investigated novel bone agents that could improve the rate of bone repair.

 

Dr Sarah Hosking 

Role: Career Development 

Dean’s Research Postdoctoral Fellow, Faculty of Health, Deakin University, Geelong, Victoria

Researcher profile: https://www.deakin.edu.au/about-deakin/people/sarah-hosking

Twitter: @smhoski 

Email: s.hosking@deakin.edu.au

Dr Sarah Hosking is a postdoctoral research fellow within the Institute for Mental and Physical Health and Clinical Translation, Deakin University. Her research focuses on the influence of health literacy in osteoporosis prevention and management. Dr Hosking is currently investigating associations between health literacy and appropriate use of medications to prevent low-trauma fracture.

 

Dr Scott Youlten

Role: TBD

Postdoctoral Research Associate in the Bone Biology Laboratory, Garvan Institute of Medical Research, Sydney

Email: s.youlten@garvan.org.au

Scott obtained his honors degree in molecular biology before diving into the world of computation biology during his PhD. This ignited his passion for skeletal genetics, big beautiful datasets and coffee - and he can be seen with a smile on his face whenever these three things coincide. Scotts research is focused on using a system-level understanding of the molecular mechanisms driving skeletal disease to reveal novel therapeutic avenues.

 

Dr Alicia Jones

Role: Clinical Training

Endocrinology Clinical Fellow (Monash Health, Vic), PhD candidate (Monash University, Vic)

Researcher Profile: https://www.researchgate.net/profile/Alicia_Jones25

Email: alicia.jones@monash.edu

Dr Alicia Jones is completing her final year of Endocrinology advanced training at Monash Health, and in her first year of a PhD at the Monash Centre for Health Research and Implementation, part of the Monash University School of Population health and Preventative Medicine. Her research is on models of care delivery in osteoporosis, to provide equitable access particularly to people living in rural areas. Clinically she works in general endocrinology clinics and diabetes clinics, and has a particular interest in metabolic bone disease and reproductive health.

 

 

Dr Victoria Leitch

Role: Communications

Research Fellow, Manufacturing, Materials and Mechatronics, RMIT University, Victoria

Researcher Profile: https://www.rmit.edu.au/contact/staff-contacts/academic-staff/l/leitch-dr-victoria

Email: leitch.victoria@gmail.com

Dr Victoria Leitch holds a Bachelor of Science (Honours) and PhD, completed at the University of Adelaide and a Master of Science Communication with the Australian National University. She has worked as a Postdoctoral Research Associate with the Origins of Bone and Disease Project based at Imperial College London, and now works on the Just-in-time implants project at RMIT University, Melbourne. Her research interests include the genetics of bone disorders, thyroid hormone and bone, osseointegration and craniofacial development.

  

Dr Niloufar Ansari

Role: TBD

Postdoctoral researcher, The Nanomaterials for Biology Group, The Monash Institute of Pharmaceutical Sciences (MIPS), Melbourne

Researcher profile: https://www.nanomb.org/group-members

Twitter @niloufar_ansari

Email: niloufar.ansari@monash.edu

Dr Niloufar Ansari is a postdoctoral researcher at The Nanomaterials for Biology Group, Monash Institute of Pharmaceutical Sciences. Currently, she works on using nanoparticles for targeted delivery of drugs, and studies the interaction of nanoparticles with the cells.

 

Dr Natalie Hyde

Role: Events

Dean’s Research Postdoctoral Fellow, Institute for Mental and Physical Health and Clinical Treatment, Deakin University, Geelong, Victoria

Researcher Profile: https://www.deakin.edu.au/about-deakin/people/natalie-hyde

Twitter: @nat_hyde

Email: natalie.hyde@deakin.edu.au

Dr Natalie Hyde is a postdoctoral research fellow at the Epi-Centre for Health Ageing, Deakin University in Geelong, Australia. To date her research has largely focused on the role of maternal vitamin D and offspring health outcomes, with a focus on musculoskeletal health. Currently she is developing a program of research investigating the role of the developmental origins of musculoskeletal health, with a particular focus on various exposures during pregnancy and musculoskeletal health in later life.

 

Dr Nicolas Hart

Role: TBD

Senior Research Fellow, Cancer Survivorship and Exercise Medicine, Queensland University of Technology

Researcher Profile: https://staff.qut.edu.au/staff/nicolas.hart

Twitter: @DrNicolasHart

Email: nicolas.hart@qut.edu.au

Dr Nicolas Hart, PhD AES CSCS ESSAM is a Senior Research Fellow, and Deputy Lead of the Cancer Survivorship Program at the Cancer and Palliative Care Outcomes Centre (Queensland University of Technology). His research focuses on the mechanobiological basis of exercise medicine to suppress tumour growth and preserve musculoskeletal mass, structure and strength in advanced cancer patients with sclerotic or osteolytic bone metastases; multiple myeloma patients with osteolytic bone disease; and general muscle-bone health in all cancer survivors through-out treatment and beyond. Dr Hart also conducts research into the pathogenesis of stress fractures, inclusive of targeted screening, prevention and remediation for elite athletes (AFL, Rugby and Soccer) and tactical operators (police and army) using the latest imaging modalities (peripheral Quantitative Computed Tomography; Dual-energy X-ray Absorptiometry; and Magnetic Resonance Imaging). He also focuses on musculoskeletal health in other clinical populations through the Western Australian Bone Research Collaboration (WABRC; www.wabrc.com) which he co-founded and co-leads.

 

Dr Jiao Jiao Li

Role: TBD

Lecturer, University of Technology Sydney

Researcher Profile: https://www.uts.edu.au/staff/jiaojiao.li

Twitter: @JiaoJiaoLi_Syd

Email: jiaojiao.li@uts.edu.au

Dr Jiao Jiao Li (JJ) is a biomedical engineer, Lecturer and NHMRC Early Career Fellow at the UTS School of Biomedical Engineering, and a chief investigator on the ARC Training Centre for Innovative BioEngineering. She is also an Honorary Associate at the Kolling Institute, University of Sydney. JJ is researching regenerative medicine approaches to treat chronic musculoskeletal conditions such as osteoarthritis and bone loss. She has particular interest in developing stem cell-based therapeutics, as well as biomaterials for tissue engineering of bones and joints.